皮下免疫治疗对儿童变应性鼻炎患者血清人β防御素-2的影响观察

目的：探讨皮下免疫治疗（subcutaneous immunotherapy，SCIT）对变应性鼻炎儿童血清人β防御素-2（human beta defensin-2，HBD-2）的影响。方法30例行SCIT的变应性鼻炎患儿入治疗组，20例健康儿童入对照组，检测对照组及治疗组治疗前、治疗后半年、1年血清HBD-2浓度，并记录鼻部症状总评分（total nasal symptom scores，TNSS）及药物评分。结果对照组、治疗组治疗前、治疗后半年、1年血清HBD-2浓度为4.62[4.08；4.87]、3.74[3.37；4.61]、4.62[4.13；5.54]、4.79[4.45；6.19]ng/ml，随着SCIT进行，HBD-2浓度逐渐上升（P<0.01）。治疗组治疗前、治疗后半年、1年TNSS分别为7.43±2.15、4.17±2.16、4.20±1.92，药物评分分别为1.25[0.75；1.38]、0.25[0；0.75]、0.25[0；0.75]。治疗组各时间点HBD-2浓度与TNSS及药物评分无明显相关（P均>0.05）。结论变应性鼻炎患者血清HBD-2浓度较正常人低，SCIT可上调变应性鼻炎患者血清HBD-2水平。

Effect of subcutaneous immunotherapy on serum levels of human beta defensin-2 in children with allergic rhinitis

OBJECTIVE To investigate the effect of subcutaneousimmunotherapy(SCIT) on levels of the serum human beta defensin-2 in children with allergic rhinitis. METHODS 30 cases of children with allergic rhinitis who were treated by SIT were selected as the treatment group, 20 cases of healthy children as the control group. Serum HBD-2 concentration of the control group was tested. Serum HBD-2 concentration of the treatment group was tested at three different time points: before SCIT, half a year after SCIT and one year after SCIT. And total nasal symptom scores(TNSS) and medication scores were recorded at each time point. RESULTS The serum HBD-2 concentration of the control group, that of the treatment group before SIT, half a year after SIT and one year after SIT were 4.62[4.08; 4.87], 3.74[3.37; 4.61], 4.62[4.13; 5.54], 4.79[4.45;6.19]ng/ml. The HBD-2 concentration gradually increased after SCIT. The TNSS of the treatment group before SCIT, half a year after SCIT and one year after SCIT were 7.43±2.15, 4.17±2.16, 4.20±1.92, The medication scores of the treatment group before SCIT, half a year after SCIT and one year after SCIT were 1.25[0.75; 1.38], 0.25[0; 0.75, 0.25[0; 0.75].There was no correlation (all P>0.05) between the serum HBD-2 concentration and TNSS or medication scores of the treatment group. CONCLUSION The serum levels of HBD-2 in patients with allergic rhinitis were lower than those in normal persons. The specific immunotherapy raised the serum HBD-2 levels of allergic rhinitis patients.